Tag
Levothyroxine therapy lowering TSH in euthyroid PTMC patients during active surveillance raises reverse T3 levels while maintaining stable free T3, suggesting altered thyroid hormone metabolism and a compensatory adaptive response.
Levothyroxine treatment in older adults with subclinical hypothyroidism shows limited impact on cardiometabolic biomarkers overall but may benefit those with higher TSH levels, highlighting nuanced treatment implications and the need for ta
A randomized trial found that levothyroxine treatment for subclinical hypothyroidism or hypothyroxinemia starting between 8 and 20 weeks of gestation did not improve IQ scores in children at age 5 years compared with placebo.
This real-world study demonstrates a dose-dependent increase in suboptimal thyroid hormone control among adults treated with levothyroxine, emphasizing the need for enhanced TSH monitoring in patients on higher doses.
Macro-TSH was rare but clinically important in patients with subclinical hypothyroidism, sometimes mimicking true thyroid disease and leading to unnecessary levothyroxine use. Specialized testing confirmed multiple immunoglobulin-linked TSH
A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.
This review analyzes the ACEL-UK-ETT emulated target trial, demonstrating that long-term levothyroxine therapy in older adults with subclinical hypothyroidism significantly reduces cardiovascular events and all-cause mortality without compr
A randomized clinical trial demonstrates that a 15% dose increase allows levothyroxine to be taken with breakfast without compromising TSH stability, significantly improving patient preference and well-being.
A longitudinal analysis from the SWAN study indicates that women treated with levothyroxine for hypothyroidism do not face a higher risk of cardiovascular events compared to those without thyroid disease, providing clinical reassurance for
This umbrella review confirms that early levothyroxine treatment significantly reduces risks of pregnancy loss and preterm delivery in women with subclinical hypothyroidism or TPOAb positivity, especially when TSH levels exceed 4.0 mU/l.
